logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Alice Bexon

university of texas system
H指数:13
被引数:911
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors
EUROPEAN JOURNAL OF CANCER
IF7.1
2024-10-010
PRE
Naumov, G.; Dulloo, S.; Fennell, D.; Lord, S.; Thistlethwaite, F.; Maskell, N.; Popat, S.; Blyth, K.; Szlosarek, P.; Aujayeb, A.; Franks, K.; Herrero, J.; Cunniff, B.; Duncan, J.; Graham, P.; Bexon, A.; Spicer, J.
RSO-021, a first-in-class covalent inhibitor of mitochondrial PRX3: From bench to bedside
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Fennell, Dean A.; Dulloo, Sean; Szlosarek, Peter; Thistlethwaite, Fiona; Lord, Simon; Rahman, Najib M.; Cunniff, Brian; Dzialo, Joanna; Poile, Charlotte; Panchal, Rakesh; Duncan, Jarrett; Graham, Pip; Bexon, Alice; Naumov, George N.; Spicer, James
ST101, a peptide antagonist of novel I/O target CEBPβ,reprograms MDSCs and promotes an immunoactive tumor microenvironment
CANCER RESEARCH
IF16.6
2023-04-140
PRE
Scuoppo, Claudio; Ramirez, Rick; Leong, Siok; Ghamsari, Lila; Capiaux, Gina; Michel, Rob; Kaesshaefer, Steve; Merutka, Gene; Kappel, Barry; Vainstein-Haras, Abi; Bexon, Alice; Rotolo, Jim
A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation

TLR9激动剂球形核酸cavrotolimod在健康参与者中的首次人体1期研究: 免疫激活的证据

FRONTIERS IN IMMUNOLOGY
IF5.9
2022-12-1314
OAAI
Daniel, Weston L. L.; Lorch, Ulrike; Mix, Scott; Bexon, Alice S. S.
ST101, A PEPTIDE ANTAGONIST OF NOVEL I/O TARGET CEBPβ, REPROGRAMS MDSC POLARIZATION AND DECREASES TUMOR-ASSOCIATED TREGS, SUGGESTING AN IMMUNE COMPONENT TO OBSERVED CLINICAL RESPONSES
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2022-11-070
OA
Scuoppo, Claudio; Falchook, Gerald; Fontana, Elisa; Williams, Anja; Lakhani, Nehal; Evans, Jeff; Iwamoto, Fabio; McKean, Meredith; Symeonides, Stefan; McLaren, Alistair; Henry, Jason; Capiaux, Gina; Michel, Robert; Kaesshaefer, Stephen; Bexon, Alice; Rotolo, Jim
First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors
ANNALS OF ONCOLOGY
IF65.4
2022-09-011
OAAI
Dulloo, S.; Fennell, D. A.; Szlosarek, P. W.; Thistlethwaite, F.; Lord, S.; Rahman, N. M.; Greystoke, A.; Cunniff, B.; Dzialo, J.; Poile, C.; Panchal, R.; Duncan, J.; Graham, P.; Bexon, A. S.; Naumov, G.; Spicer, J.
Phase 1 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in patients with advanced solid tumors, with a phase 2 expansion in patients with hormone receptor positive breast cancer (HR+ BC)
CANCER RESEARCH
IF16.6
2022-02-150
PRE
Bexon, Alice S.; Arkenau, Hendrik-Tobias; Evans, Jeff; Falchook, Gerald S.; Symeonides, Stefan N.; McKean, Meredith A.; Fontana, Elisa; Bupath, Manojkumar; McLaren, Alistair; Chandana, Sreenivasa; Ding, Tze-en; Lim, Emerson A.; Rotolo, Jim; Capiaux, Gina; Michel, Rob; Kaesshaefer, Stephen; Lakhani, Nehal J.
ST101, a peptide targeting oncogenic transcription factor C/EBPβ: initial safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) data from an ongoing phase 1 dose escalation study in patients with advanced, metastatic solid tumors
MOLECULAR CANCER THERAPEUTICS
IF5.5
2021-12-010
PRE
Lakhani, Nehal J.; Arkenau, Hendrik-Tobias; Symeonides, Stefan N.; Evans, Jeffry; McKean, Meredith A.; Fontana, Elisa; Bupath, Manojkumar; McLaren, Alistair; Chandana, Sreenivasa; Ding, Tze-en; Lim, Emerson A.; Rotolo, Jim; Capiaux, Gina; Michel, Rob; Kaesshaefer, Stephen; Bexon, Alice S.; Falchook, Gerald S.
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients with urothelial carcinoma
MOLECULAR CANCER THERAPEUTICS
IF5.5
2021-12-010
PRE
Miest, Tanner S.; Leibovich, Bradley; Bardot, Stephen; Young, Paul R.; Boorjian, Stephen A.; Gonzalgo, Mark; Herrera-Hernandez, Loren; Tollefson, Matthew K.; Karnes, Jeffrey; Nichols, Paige; Kroeninger, Tessa; Graham, Rachel; Lahana, Carole; Reckner, Monica; Newsom, Alysha; Packiriswamy, Nandakumar; Anoka, Janice; Peng, Kah Whye; Wiegert, Erol; Bexon, Alice; Naik, Shruthi
SAFETY AND EFFICACY OF NEOADJUVANT INTRAVESICAL ONCOLYTIC MV-NIS IN PATIENTS WITH UROTHELIAL CARCINOMA
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2021-11-100
OA
Miest, Tanner; Leibovich, Bradley; Bardot, Stephen; Young, Paul; Boorjian, Stephen; Gonzalgo, Mark; Herrera-Hernandez, Loren; Tollefson, Matthew; Karnes, Jeffrey; Nichols, Paige; Kroeninger, Tessa; Graham, Rachel; Lahana, Carole; Reckner, Monica; Newsom, Alysha; Packiriswamy, Nandakumar; Anoka, Janice; Peng, Kah Whye; Wiegert, Erol; Bexon, Alice; Naik, Shruthi
RELATIONSHIP OF INFUSION DURATION AND DOSE TO SAFETY, EFFICACY AND PHARMACODYNAMICS: SECOND PART OF A PHASE 1-2 STUDY USING VSV-IFNβ-NIS (VV1) ONCOLYTIC VIRUS IN PATIENTS WITH REFRACTORY SOLID TUMORS
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2021-11-101
OA
Patel, Manish; Powell, Steven; Strauss, James; Johnson, Melissa; Cripe, Timothy; Peng, Kah-Whye; Russell, Stephen; Russell, Luke; Reckner, Monica; Wiegert, Erol; Bexon, Alice; Merchan, Jaime
Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors
ANNALS OF ONCOLOGY
IF65.4
2021-09-010
OAAI
Mckean, M. A.; Lakhani, N. J.; Arkenau, H-T.; Symeonides, S.; Evans, T. R. J.; Lim, E. A.; Fontana, E.; Bupathi, M.; Mclaren, A.; Chandana, S. R.; Ding, T-E.; Rotolo, J.; Capiaux, G.; Michel, R.; Kaesshaefer, S.; Bexon, A.; Falchook, G. S.
IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

免疫COV v2.0: 用于测量SARS-CoV-2-Neutralizing抗体滴度的高通量临床测定的开发和验证

MSPHERE
IF3.1
2021-06-3015
OAAI
Vandergaast, Rianna; Carey, Timothy; Reiter, Samantha; Lathrum, Chase; Lech, Patrycja; Gnanadurai, Clement; Haselton, Michelle; Buehler, Jason; Narjari, Riya; Schnebeck, Luke; Roesler, Anne; Sevola, Kara; Suksanpaisan, Lukkana; Bexon, Alice; Naik, Shruthi; Brunton, Bethany; Weaver, Scott C.; Rafael, Grace; Tran, Sheryl; Baum, Alina; Kyratsous, Christos A.; Peng, Kah Whye; Russell, Stephen J.
SAFETY AND PRELIMINARY EFFICACY OF INTRATUMORAL CAVROTOLIMOD (AST-008), A SPHERICAL NUCLEIC ACID TLR9 AGONIST, IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
JOURNAL FOR IMMUNOTHERAPY OF CANCER
IF10.6
2020-12-1010
PREAI
O'Day, Steven; Perez, Cesar; Wise-Draper, Trisha; Hanna, Glenn; Bhatia, Shailender; Kelly, Ciara; Medina, Theresa; Laux, Douglas; Daud, Adil; Chandra, Sunandana; Shaheen, Montaser; Gao, Ling; Burgess, Melissa; Hernandez-Aya, Leonel; Yeung, Cecilia; Smythe, Kimberly; DeGoma, Emil; Daniel, Weston; Feltner, Douglas; Sindelar, Laurel; Michel, Robert; Bexon, Alice; Bexon, Martin; Milhem, Mohammed
Phase 1b/2 study of an intratumoral TLR9 agonist spherical nucleic acid (AST-008) and pembrolizumab: Evidence of immune activation
CANCER RESEARCH
IF16.6
2020-08-151
PRE
Milhem, Mohammed M.; Perez, Cesar A.; Hanna, Glenn J.; Wise-Draper, Trisha M.; Bhatia, Shailender; Bexon, Alice S.; Daniel, Weston L.; O'Day, Steven J.
Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity
DRUG SAFETY
IF3.8
2020-06-2711
OAAI
Lewis, James H.; Cottu, Paul H.; Lehr, Martin; Dick, Evan; Shearer, Todd; Rencher, William; Bexon, Alice S.; Campone, Mario; Varga, Andrea; Italiano, Antoine
Oncolytic Measles Virotherapy and Opposition to Measles Vaccination
MAYO CLINIC PROCEEDINGS
IF6.7
2019-09-0110
OAAI
Russell, Stephen J.; Babovic-Vuksanovic, Dusica; Bexon, Alice; Cattaneo, Roberto; Dingli, David; Dispenzien, Angela; Deyle, David R.; Federspiel, Mark J.; Fielding, Adele; Galanis, Eva; Lacy, Martha Q.; Leibovich, Bradley C.; Liu, Minetta C.; Munoz-Alia, Miguel; Miest, Tanner C.; Molina, Julian R.; Mueller, Sabine; Okuno, Scott H.; Packiriswamy, Nandakumar; Peikert, Tobias; Raffel, Corey; Van Rhee, Frits; Ungerechts, Guy; Young, Paul R.; Zhou, Yumei; Peng, Kah-Whye
Rational design of an oncolytic virus permits use of interferon beta as a pharmacodynamic marker for clinical application
CANCER RESEARCH
IF16.6
2019-07-010
PRE
Cripe, Timothy P.; Bakkum-Gamez, Jamie; Merchan, Jaime R.; Lacy, Martha Q.; Patel, Manish R.; Powell, Steven; Strauss, James; Zhang, Lianwen; Sakuma, Toshie; Diaz, Memy; Packiriswamy, Nandakumar; Upreti, Deepak; Brunton, Bethany; Jevremovic, Dragan; Russell, Stephen J.; Bexon, Alice; Peng, Kah-Whye
AST-008, a TLR9 agonist spherical nucleic acid, activated NK cells, T cells, and cytokines in healthy subjects in a Phase I clinical trial
CANCER RESEARCH
IF16.6
2019-07-016
PRE
Daniel, Weston L.; Lorch, Ulrike; Coates, Simon; Bexon, Alice S.; Mix, Scott
Preliminary correlative and clinical data from a first-in-human (FIH) study of the intratumoral (IT) oncolytic virotherapy, Voyager-V1, in patients with solid tumors
CANCER RESEARCH
IF16.6
2018-07-011
PRE
Powell, Steven; Patel, Manish R.; Merchan, Jaime R.; Cripe, Timothy P.; Strauss, James; Diaz, Rosa M.; Packiriswamy, Nandakumar; Brunton, Bethany A.; Upreti, Deepak; Khan, Rehan; Suksanpaisan, Lukkana; Vandergaast, Rianna; Russell, Stephen J.; Bexon, Alice S.; Peng, Kah Whye

研究方向

暂未获取到该数据
E
E Gilles
H 指数:9论文数:72被引数:372
K
Keyvan Rezaï
H 指数:25论文数:180被引数:3,492
S
Stefan Proniuk
H 指数:13论文数:44被引数:495
G
Gina Capiaux
H 指数:4论文数:19被引数:330
F
François Lokiec
H 指数:34论文数:272被引数:4,223
N
Nehal J. Lakhani
H 指数:28论文数:283被引数:4,385
S
Stephen J. Russell
H 指数:106论文数:854被引数:4.3万
M
Mario Campone
H 指数:93论文数:1,065被引数:5.2万
E
Elisa Fontana
H 指数:20论文数:216被引数:1,874
P
Paul Cottu
H 指数:53论文数:529被引数:1.0万